<DOC>
	<DOCNO>NCT00673569</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue patient cancer laboratory may help doctor learn change may occur DNA identify biomarkers related cancer . It may also help doctor learn well patient respond treatment . PURPOSE : This phase II trial study well laboratory test predict response erlotinib patient metastatic unresectable non-small cell lung cancer respond previous treatment .</brief_summary>
	<brief_title>Laboratory Test Predicting Response Erlotinib Patients With Relapsed Metastatic Unresectable Non-Small Cell Lung Cancer That Did Not Respond Previous Treatment</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether extent inhibition ERK phosphorylation lung cancer cell expose ex vivo vivo erlotinib hydrochloride significantly differ respond nonresponding patient relapse , metastatic unresectable non-small cell lung cancer . Secondary - Determine whether extent inhibition epidermal growth factor receptor ( EGFR ) AKT phosphorylation lung cancer cell expose ex vivo vivo erlotinib hydrochloride significantly differ 2 group patient . - Correlate extent inhibition EGFR , ERK , AKT phosphorylation lung cancer cell expose ex vivo erlotinib hydrochloride vivo objective tumor response erlotinib hydrochloride patient . - Correlate EGFR gene mutation amplification status pharmacodynamic evidence response erlotinib hydrochloride patient . OUTLINE : This open-label , pilot study . Patients receive oral erlotinib hydrochloride daily day 1-28 . Treatment repeat every 28 day least 2 course absence disease progression unacceptable toxicity . Patients undergo tumor fine-needle aspiration biopsy ultrasound CT scan guidance baseline day 12-15 laboratory study . Laboratory study include quantitative western blot enzyme-linked immunosorbent assay , gene mutation amplification , ex vivo assay . Tumor cell also analyze change phosphorylation status and/or expression level pharmacodynamic marker , include total- phospho-epidermal growth factor receptor , total- phospho-ERK , total- phospho-AKT . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic unresectable nonsmall cell lung cancer Relapsed disease Failed ≥ 1 prior chemotherapy regimen Measurable disease Tumor must accessible fineneedle aspiration No uncontrolled brain metastasis Patients brain metastasis must stable neurologic status local therapy ( surgery radiotherapy ) ≥ 4 week neurologic dysfunction would preclude evaluation neurologic adverse event PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Life expectancy &gt; 12 week WBC &gt; 3,000/mm³ Absolute neutrophil count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Bilirubin normal PT activate PTT normal Creatinine normal OR creatinine clearance &gt; 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled intercurrent illness , include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude study compliance No significant ophthalmologic abnormalities* , include follow : Severe dry eye syndrome Keratoconjunctivitis sicca Sjögren 's syndrome Severe exposure keratopathy Disorders might increase risk epitheliumrelated complication ( e.g. , bullous keratopathy , aniridia , severe chemical burn , neutrophilic keratitis ) No serious , nonhealing wound , ulcer , bone fracture No significant traumatic injury within past 14 day NOTE : *Patients mild form ophthalmologic abnormality , asymptomatic history , normal ophthalmologic examination allow discretion investigator . Patients treatable condition ( e.g. , infectious keratitis/conjunctivitis allergic conjunctivitis ) allow treatment resolution condition . PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior small molecule inhibitor epidermal growth factor receptor , include erlotinib hydrochloride gefitinib At least 4 week since prior anticancer therapy , include chemotherapy , radiotherapy , biologic therapy , investigational therapy ( 6 week nitrosoureas mitomycin C ) More 14 day since prior major surgery open biopsy recover At least 7 day since prior concurrent inhibitor CYP3A4 , include follow : Itraconazole Herbal extract tincture , include follow : Hydrastis canadensis ( goldenseal ) Uncaria tomentosa ( cat 's claw ) Echinacea angustifolia root Trifolium pratense ( wild cherry ) Chamomile Licorice root Dillapiol Naringenin No concurrent inducer CYP3A4 , include follow : Phenytoin Carbamazepine Rifampin Barbiturates Hypericum perforatum ( St. John 's wort ) No concurrent chemotherapy No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient No concurrent radiotherapy , include palliative radiotherapy No concurrent therapeutic anticoagulation No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>